The Oncology Institute, Inc. TOI Clinical trials & other — Depreciation expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s clinical trials & other — depreciation expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s clinical trials & other — depreciation expense?
- The Oncology Institute, Inc. (TOI) reported clinical trials & other — depreciation expense of $0 in Q1 2026.
- How has The Oncology Institute, Inc.'s clinical trials & other — depreciation expense changed year-over-year?
- The Oncology Institute, Inc.'s clinical trials & other — depreciation expense decreased by 100.0% year-over-year, from $2K to $0.
- What is the long-term trend for The Oncology Institute, Inc.'s clinical trials & other — depreciation expense?
- Over 3 years (2021 to 2025), The Oncology Institute, Inc.'s clinical trials & other — depreciation expense has grown at a -59.5% compound annual growth rate (CAGR), from $151K to $10K.
- What does clinical trials & other — depreciation expense mean?
- This metric represents the portion of the cost of tangible fixed assets allocated to the clinical trials and other business segment over their useful lives. It reflects the wear and tear or obsolescence of equipment and infrastructure used to support research and auxiliary services.